GSK Investigational Site

Vienna A-1220

2 studies enrolling now · 48 studies all time

What they study most

Alzheimer's Disease, Anaemia, Arthritis, Rheumatoid, Aspergillosis, Allergic Bronchopulmonary, Asthma, Bowel Dysfunction, Breast Neoplasms, Chemotherapy-Induced Nausea and Vomiting, Constipation, Crohn's Disease, Diabetes Mellitus, Type 2, HIV

Studies at this site

• A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study — Recruiting now
• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) — Recruiting now
• A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF — Completed
• Extended Access of Momelotinib in Adults With Myelofibrosis — Running, not enrolling
• A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype — Completed
• Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry — Completed
• Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease — Running, not enrolling
• A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed — Completed
• A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer — Completed
• Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) — Completed
• A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor — Stopped early
• GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer — Stopped early
• Dolutegravir Expanded Access Study — Completed
• A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. — Completed
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease — Completed
• 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old — Completed
• A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) — Completed
• GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma — Completed
• An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease — Stopped early
• Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide — Completed
• Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease — Completed
• Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers — Stopped early
• A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease — Completed
• Open-Label Extension Study of GSK1605786A — Stopped early
• A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) — Completed
• A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) — Stopped early
• GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease — Stopped early
• Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain — Completed
• GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults — Completed
• Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease — Completed
• RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag — Completed
• SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy — Completed
• COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis — Completed
• Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. — Stopped early
• Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole — Completed
• "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk — Completed
• Rosiglitazone on Microalbuminuria in Type 2 Diabetics — Completed
• Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer — Completed
• Brain Metastases In ErbB2-Positive Breast Cancer — Stopped early
• Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain — Completed
• Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma — Completed
• Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer — Completed
• Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy — Completed
• Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery — Completed
• Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting — Completed
• KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks — Completed